OBJECTIVE: GH is usually the first pituitary hormone to be affected following a pathological insult to the pituitary; however, data on the prevalence of GH deficiency in patients with nonsecreting pituitary microadenomas and normal serum IGF-1 levels are scarce. This study aims to evaluate the prevalence of GH and other anterior pituitary hormone deficiencies, and to determine whether microadenomas per se could be associated with reduced GH response rates to GHRH-arginine stimulation. DESIGN: Analytical, retrospective, two-site case-control study. PATIENTS AND METHODS: Thirty-eight patients with nonsecreting pituitary microadenomas (mean size 4.2 mm) and normal serum IGF-1 levels were studied. Anterior pituitary function testing, including the GHRH-arginine test to examine GH reserve, was performed in all patients. Serum IGF-1 levels and peak GH levels in the patients that passed the GHRH-arginine test were compared with 22 age- and BMI-matched healthy controls. RESULTS: Nineteen patients (50%) failed the GHRH-arginine test and had higher body mass index (BMI) than those that passed the GHRH-arginine test and healthy controls. Peak GH levels in patients that passed the GHRH-arginine test were lower compared to healthy controls and 19 patients (50%) had at least one other pituitary hormone deficit. A negative correlation (r = -0.42, P < 0.01) between peak GH levels and BMI was identified, but no correlations were found between peak GH and serum IGF-1 levels. CONCLUSIONS: Our data demonstrated that a substantial number of patients with nonsecreting pituitary microadenomas failed the GHRH-arginine test despite normal serum IGF-1 levels, and had at least one other pituitary hormone deficiency, suggesting that nonsecreting microadenomas may not be clinically harmless. We therefore recommend long-term follow-up with periodic basal pituitary function testing, and to consider dynamic pituitary testing should clinical symptoms arise in these patients.
OBJECTIVE: GH is usually the first pituitary hormone to be affected following a pathological insult to the pituitary; however, data on the prevalence of GH deficiency in patients with nonsecreting pituitary microadenomas and normal serum IGF-1 levels are scarce. This study aims to evaluate the prevalence of GH and other anterior pituitary hormone deficiencies, and to determine whether microadenomas per se could be associated with reduced GH response rates to GHRH-arginine stimulation. DESIGN: Analytical, retrospective, two-site case-control study. PATIENTS AND METHODS: Thirty-eight patients with nonsecreting pituitary microadenomas (mean size 4.2 mm) and normal serum IGF-1 levels were studied. Anterior pituitary function testing, including the GHRH-arginine test to examine GH reserve, was performed in all patients. Serum IGF-1 levels and peak GH levels in the patients that passed the GHRH-arginine test were compared with 22 age- and BMI-matched healthy controls. RESULTS: Nineteen patients (50%) failed the GHRH-arginine test and had higher body mass index (BMI) than those that passed the GHRH-arginine test and healthy controls. Peak GH levels in patients that passed the GHRH-arginine test were lower compared to healthy controls and 19 patients (50%) had at least one other pituitary hormone deficit. A negative correlation (r = -0.42, P < 0.01) between peak GH levels and BMI was identified, but no correlations were found between peak GH and serum IGF-1 levels. CONCLUSIONS: Our data demonstrated that a substantial number of patients with nonsecreting pituitary microadenomas failed the GHRH-arginine test despite normal serum IGF-1 levels, and had at least one other pituitary hormone deficiency, suggesting that nonsecreting microadenomas may not be clinically harmless. We therefore recommend long-term follow-up with periodic basal pituitary function testing, and to consider dynamic pituitary testing should clinical symptoms arise in these patients.
Authors: Helen Simpson; Richard Savine; Peter Sönksen; Bengt-Ake Bengtsson; Lena Carlsson; Jens Sandahl Christiansen; David Clemmons; Pinchus Cohen; Raymond Hintz; Ken Ho; Primus Mullis; Iain Robinson; Christian Strasburger; Toshiaka Tanaka; Michael Thorner Journal: Growth Horm IGF Res Date: 2002-02 Impact factor: 2.372
Authors: Xiao-Dan Qu; Irene T Gaw Gonzalo; Mohammed Y Al Sayed; Pejman Cohan; Peter D Christenson; Ronald S Swerdloff; Daniel F Kelly; Christina Wang Journal: J Clin Endocrinol Metab Date: 2004-12-21 Impact factor: 5.958
Authors: Ulla Feldt-Rasmussen; Roger Abs; Bengt-Ake Bengtsson; Helge Bennmarker; Margareta Bramnert; Elizabeth Hernberg-Ståhl; John P Monson; Björn Westberg; Patrick Wilton; Christian Wüster Journal: Eur J Endocrinol Date: 2002-01 Impact factor: 6.664
Authors: G Aimaretti; G Corneli; P Razzore; S Bellone; C Baffoni; E Arvat; F Camanni; E Ghigo Journal: J Clin Endocrinol Metab Date: 1998-05 Impact factor: 5.958
Authors: M R Valetto; J Bellone; C Baffoni; P Savio; G Aimaretti; L Gianotti; E Arvat; F Camanni; E Ghigo Journal: Eur J Endocrinol Date: 1996-11 Impact factor: 6.664
Authors: Ameeta Mehta; Peter C Hindmarsh; Richard G Stanhope; Caroline E Brain; Michael A Preece; Mehul T Dattani Journal: J Clin Endocrinol Metab Date: 2003-12 Impact factor: 5.958
Authors: Vivien Bonert; John Carmichael; Zengru Wu; James Mirocha; Daniel A Perez; Nigel J Clarke; Richard E Reitz; Michael J McPhaul; Adam Mamelak Journal: Pituitary Date: 2018-02 Impact factor: 4.107
Authors: Laura E Dichtel; Kevin C J Yuen; Miriam A Bredella; Anu V Gerweck; Brian M Russell; Ariana D Riccio; Michelle H Gurel; Patrick M Sluss; Beverly M K Biller; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2014-12 Impact factor: 5.958
Authors: Pamela U Freda; Albert M Beckers; Laurence Katznelson; Mark E Molitch; Victor M Montori; Kalmon D Post; Mary Lee Vance Journal: J Clin Endocrinol Metab Date: 2011-04 Impact factor: 5.958
Authors: Pamela U Freda; Jeffrey N Bruce; Alexander G Khandji; Zhezhen Jin; Richard A Hickman; Emily Frey; Carlos Reyes-Vidal; Marc Otten; Sharon L Wardlaw; Kalmon D Post Journal: J Endocr Soc Date: 2020-02-18